Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PARG | Q86W56 | 1/20 | 0.34 |
| ▸ | PTGDR | Q13258 | 1/20 | 0.33 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.32 |
| ▸ | BRD4 | O60885 | 1/20 | 0.31 |
| ▸ | BRAF | P15056 | 1/20 | 0.31 |
| ▸ | ENPP2 | Q13822 | 2/20 | 0.31 |
| ▸ | ATXN2 | Q99700 | 2/20 | 0.31 |
| ▸ | PARP1 | P09874 | 1/20 | 0.31 |
| ▸ | SFRP1 | Q8N474 | 1/20 | 0.31 |
| ▸ | CCR8 | P51685 | 1/20 | 0.30 |
| ▸ | TSHR | P16473 | 1/20 | 0.30 |
| ▸ | CNR1 | P21554 | 1/20 | 0.30 |
| ▸ | HRH1 | P35367 | 1/20 | 0.30 |
| ▸ | CCR3 | P51677 | 1/20 | 0.30 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3255657 | 0.87 | PARG (0.38) | PARGTDP1BRD4BRAFSFRP1 | |
| SCHEMBL3255653 | 0.87 | PARG (0.38) | PARGTDP1BRD4BRAFSFRP1 | |
| Butyric Acid SCHEMBL4157941 | 0.84 | PARG (0.38) | PARGPTGDRTDP1BRD4BRAF | |
| SCHEMBL4161246 | 0.82 | PARG (0.50) | PARGPTGDRTDP1BRD4BRAF | |
| SCHEMBL4717788 | 0.82 | PARG (0.42) | PARGTDP1BRD4BRAFPARP1 | |
| SCHEMBL4161880 | 0.80 | BRD4 (0.43) | BRD4 | |
| SCHEMBL4164931 | 0.80 | PARG (0.45) | PARGPTGDRTDP1BRAFENPP2 | |
| SCHEMBL4153573 | 0.78 | PARG (0.52) | PARGPTGDRTDP1BRD4BRAF | |
| SCHEMBL4165046 | 0.78 | PARG (0.44) | PARGPTGDRTDP1BRAFENPP2 | |
| SCHEMBL4163004 | 0.77 | PARG (0.43) | PARGPTGDRTDP1BRAFENPP2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8426437-B2 | Pyrroloquinoline derivatives and their use as protein kinases inhibitors | PIERRE FABRE MEDICAMENT (FR) | 2013-04-23 | — | — | US | disclosed |
| US-20090042876-A1 | Pyrroloquinoline Derivatives And Their Use As Protein Kinases Inhibitors | PIERRE FABRE MEDICAMENT (FR) | 2009-02-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090042876-A1 | Pyrroloquinoline Derivatives And Their Use As Protein Kinases Inhibitors | MAP3K1, MAP3K2, MAP3K7 | PARG 3507/4885PTGDR 861/4885TDP1 1098/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.